newsfilter
← Latest News
GlobeNewswire·

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of this trial MALVERN, Pa., June